Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NY:AMRX)

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Earnings Scheduled For November 4, 2022
Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of $49.95 million. • Telefonica (NYSE:TEF) is likely to report earnings for... 
Via Benzinga
Amneal Seeks FDA Approval For Its Parkinson's Candidate
 
Via Benzinga
Amneal Pharma Posts Mixed Q2 Earnings, Cuts Profit Outlook For 2022
 
Via Benzinga
Recap: Amneal Pharmaceuticals Q2 Earnings
  Amneal Pharmaceuticals (NYSE:AMRX) reported its Q2 earnings results on Friday, August 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Amneal Pharmaceuticals Q1 Earnings
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Outlook For Amneal Pharmaceuticals
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Friday, 2022-11-04. Here's what investors need to know before the announcement. Analysts estimate that Amneal... 
Via Benzinga
Amneal Receives FDA Approval for Leuprolide Acetate Injection
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Third Quarter 2022 Results on November 4, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty
From Amneal Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal supports Congress’ efforts to ensure essential medicines are Made in America
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal launches 4 new Generic products, including Vasopressin single-dose
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 22 companies reached new 52-week lows. 
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Amneal Reports Second Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million. 
Via Benzinga
Amneal Pharmaceuticals's Earnings: A Preview
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Amneal... 
Via Benzinga
Amneal Appoints Deborah M. Autor to Board of Directors
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Second Quarter 2022 Results on August 5, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 2022 Jefferies Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conferences in May
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Amneal Reports First Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals's Earnings Outlook
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.